Skip to content

Study on the mechanism of bone destruction mediated by pyrodeath gene in rheumatoid arthritis and ankylosing spondylitis

Study on the mechanism of bone destruction mediated by pyrodeath gene in rheumatoid arthritis and ankylosing spondylitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071640
Enrollment
Unknown
Registered
2023-05-20
Start date
2023-05-17
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis, ankylosing spondylitis

Interventions

Rheuamtoid Arthritis:None
ankylosing spondylitis:None

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers: 1. A history of diagnosis and treatment of rheumatic immune diseases (including but not limited to ankylosing spondylitis and rheumatoid arthritis) should be excluded for healthy volunteers. 2. Age 18-85, gender unlimited. 3. Informed consent and sign the informed consent. Rheumatoid arthritis and ankylosing spondylitis patients: 1. Confirmed clinical diagnosis of rheumatoid arthritis (meeting the EULAR/ACR2010 diagnostic criteria) or ankylosing spondylitis (meeting the 1984 New York criteria or the 2009 ASAS diagnostic criteria for axial spinal arthritis). 2. Age 18-85, gender unlimited. 3. Informed and consenting.

Exclusion criteria

Exclusion criteria: (1) Received intra-articular, intramuscular or intravenous corticosteroids, including adrenotropic hormone, or other medications within 4 weeks; (2) Overlap with other autoimmune diseases such as gouty arthritis, systemic lupus erythematosus, etc.; (3) Patients who had previously used fusion protein biologics (including Esep, Qiangke, Amberol, Enli, etc.) before the operation stopped < 4 weeks, patients who had used monoclonal antibody biologics (including adalimumab, Infliximab, tozizumab, etc.) before the operation stopped < 4 weeks (4) Patients with serious diseases of vital organs such as cardiovascular, brain, liver, lung, kidney and hematopoietic system, acute and chronic infectious diseases, malignant tumors, and psychiatric diseases.

Design outcomes

Primary

MeasureTime frame
Expression of pyroptosis-related genes in CD8+T cells and neutrophils;Serum bone destruction related index and disease activity evaluation index;

Secondary

MeasureTime frame
DAS28;BASDAI;

Countries

China

Contacts

Public ContactChen Xiumin

Guangdong Provincial Hospital of Chinese Medicine

candy011011@gzucm.edu.cn+86 137 6339 3464

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026